How is MT-1 (Melanotan I) administered?
This describes how MT-1 (Melanotan I) is typically administered in clinical and research references, not a self-administration guide. The usual route is Subcutaneous, on a daily loading → 1-2x weekly maintenance schedule, generally over loading 2-3 wks, then maintenance. Specific dosing is individual and beyond general information, and human evidence for MT-1 (Melanotan I) is limited.
Administration at a glance (reference data)
- Route: Subcutaneous
- Schedule: Daily loading → 1-2x weekly maintenance
- Cycle length: Loading 2-3 wks, then maintenance
- Half-life: ~1 hour
References
- Afamelanotide for Erythropoietic Protoporphyria (Scenesse approval data) — Langendonk JG et al., NEJM, 2015
- Skin pigmentation and pharmacokinetics of melanotan-I in humans — Ugwu SO, Blanchard J, Dorr RT, Levine N, et al.; Biopharmaceutics & Drug Disposition; 1997
- Afamelanotide: An Orphan Drug with Potential for Broad Dermatologic Applications — Wu J, Cotliar R; Journal of Drugs in Dermatology; 2021
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on MT-1 (Melanotan I)
Full MT-1 (Melanotan I) breakdownMT-1 (Melanotan I) what it's used forMT-1 (Melanotan I) side effectsMT-1 (Melanotan I) mistakes to avoidMT-1 (Melanotan I) who should avoid itMT-1 (Melanotan I) half-lifeMT-1 (Melanotan I) how long to workMT-1 (Melanotan I) legal statusMT-1 (Melanotan I) how it worksmt 1 vs mt 2Ask the AI Coach
Last updated 2026-06-15.